{
    "clinical_study": {
        "@rank": "61897", 
        "arm_group": [
            {
                "arm_group_label": "Part 1 (GZFD00111/TDU12766): Genz-682452", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a single oral dose of Genz-682452. Six ascending single doses and an optional seventh dose under fasted conditions will be used."
            }, 
            {
                "arm_group_label": "Part 1 (GZFD00111/TDU12766): Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will receive a single oral dose of placebo."
            }, 
            {
                "arm_group_label": "Part 2 (GZFD00211/FED12767): Genz-682452", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive two single doses of Genz-682452 separated by a 7-day wash-out period, one dose given under fed (standardized high-fat breakfast) and one under fasted conditions. The dose will be based on the blind review of the safety/tolerability/pharmacokinetic data of single dose level cohorts in Part 1."
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to assess the tolerability, safety and pharmacokinetic\n      parameters of Genz-682452 in healthy adult males, in two parts.\n\n      Part 1 (GZFD00111TDU12766): double-blind, randomized, placebo-controlled, sequential\n      ascending single dose study;\n\n      Part 2 (GZFD00211FED12767): open-label, randomized, 2-sequence, 2-period, 2-treatment\n      crossover study with a minimum wash-out period; to obtain preliminary information on the\n      pharmacokinetics,  tolerability and safety of Genz-682452 after single oral doses in fed and\n      fasted conditions.\n\n      Subjects are not allowed to participate in more than 1 part of the study."
        }, 
        "brief_title": "Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight between 50.0 and 100.0 kg, inclusive, body mass index between 18.0 and\n             32.0 kg/m^2, inclusive.\n\n          -  Certified as healthy by a comprehensive clinical assessment (detailed medical history\n             and complete physical examination).\n\n        Exclusion Criteria:\n\n          -  Any history or presence of clinically relevant cardiovascular, pulmonary,\n             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,\n             osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or\n             signs of acute illness.\n\n          -  Frequent headaches and/or migraine, recurrent nausea and/or vomiting.\n\n          -  Blood donation, greater than 100 mL, within 2 months before inclusion.\n\n          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and\n             treated by a physician.\n\n          -  History or presence of drug or alcohol abuse.\n\n          -  Unable to stop smoking cigarettes during the study.\n\n          -  Excessive consumption of beverages containing xanthine bases."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674036", 
            "org_study_id": "GZFD00111/GZFD00211", 
            "secondary_id": "TDU12766/FED12767"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part 1 (GZFD00111/TDU12766): Genz-682452", 
                    "Part 2 (GZFD00211/FED12767): Genz-682452"
                ], 
                "description": "Capsules for oral administration.", 
                "intervention_name": "Genz-682452", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 1 (GZFD00111/TDU12766): Placebo", 
                "description": "Placebo to Genz-682452", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single Oral Doses of Genz-682452 With a Pilot Investigation of Food Effect in Healthy Adult Male Subjects.", 
        "overall_official": {
            "affiliation": "Genzyme, a Sanofi Company", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events in Part 1", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "measure": "Number of participants with adverse events in Part 2", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674036"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics Plasma Parameters for Part 1 as measured by Cmax, tmax, AUC last, AUC, t1/2z, Vss/F, CL/F", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 5"
            }, 
            {
                "measure": "Pharmacokinetics Urine Parameters for Part 1 as measured by assessment of Genz-682452 urinary excretion, Ae0-t, fe0-t", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 5"
            }, 
            {
                "measure": "Pharmacokinetics Plasma Parameters for Part 2 as measured by Cmax, tmax, tlag, AUC last, AUC, t1/2z", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 3"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}